CTMC is a joint venture between Resilience and MD Anderson Cancer Center. We bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.
CTMC - a joint venture between Resilience + MD Anderson Cancer Center的外部链接
2130 W Holcombe Blvd
US，Texas，Houston，77030
CTMC - a joint venture between Resilience + MD Anderson Cancer Center转å‘了
BREAKING: The #FDA granted standard approval to pembrolizumab + trastuzumab and chemotherapy for the treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. https://hubs.li/Q03czVpq0
We're #hiring a new Specialist III, Project and Alliance Leadership in Houston, Texas. Apply today or share this post with your network.
"???? ???????????????? ?????????????????? ?????????????? ????????????????????, ?????????????? '????????-??????-????????' ??????-?? ???????? ???????????? ?????????????? ?????? ???? ??????????????????, ???????????????? ?????????????????? ???????????????????? ???????????? ?????????????? ?????????? ??????????????," says Jon Pileggi. A big thank you to Caitlin Smith at Biocompare for a comprehensive deep dive into how engineered CARs are transforming cancer treatment. Pileggi, alongside other experts, explores how logic gating, CRISPR, and other cutting-edge technologies are reducing toxicity, reshaping the tumor microenvironment, and expanding the potential of CAR-T therapy beyond blood cancers to solid tumors. Check out the full article to learn how these advancements are accelerating the future of cell therapy! #celltherapy #innovation #curecancer https://lnkd.in/ggDq-Rfm
We’re thrilled to continue our collaboration with the Ori Biotech team to accelerate cell therapy manufacturing and bring life-changing treatments to patients faster.
One of our expert TIL specialists, Marie-Andrée Forget, is making the most of the sunny San Diego weather while attending the Society for Immunotherapy of Cancer (SITC) Spring Scientific. She’s joining top minds in the field to discuss the latest advancements in solid tumor treatments and the challenges that come with them. Marie will be presenting her poster, "Integrated Solutions to Develop Better and Simpler TIL Manufacturing," showcasing CTMC’s innovative TIL platform. This approach streamlines processes, integrates cutting-edge technologies, and drives efficiencies to reduce costs and accelerate timelines—bringing impactful therapies to patients faster. At CTMC, we know TILs! #celltherapy #TILtherapy #curecancer
In this in-depth analysis in Cell & Gene Therapy Review, industry leaders highlight the biggest challenges facing the field in 2025—while focusing on actionable solutions. From scalability and financing to technology advancements and accessibility, the discussion covers critical topics shaping the industry's future. Our CEO, Jason Bock, also shares insights on the importance of patient-adjacent manufacturing models. Rather than a bleak outlook, this review emphasizes innovation, resilience, and the progress driving the field forward. #celltherapy #patientadjacent #curecancer https://lnkd.in/ervmSwXN
It was a pleasure to host the team from Celltrion Inc, headquartered in Incheon, South Korea, for a visit to our facility.? #celltherapy #curecancer
Jason Bock shares why a patient-adjacent manufacturing model is essential when developing a therapy that begins and ends with the patient. Listen to Nicole R.'s informative interview on pharmaphorum's podcast. #celltherapy #personalizedmedicine #curecancer https://lnkd.in/gAgMxzav
CTMC’s Nikola Radojevic had a fantastic opportunity to speak on a Texas Medical Center-hosted panel about careers in biotech manufacturing. Biopath@TMC is dedicated to building a diverse, skilled workforce to meet the rising demand for biomanufacturing professionals while also introducing the field to high school students. As the industry experiences rapid growth, TMC and its partners, BridgeYear, Learning Undefeated, and Houston ISD, are expanding access to career pathways for the next generation of talent. #biotech #celltherapy #curecancer
Always a pleasure to host Qasim Rizvi, CEO of KSQ Therapeutics, Inc. at our facility! We had insightful discussions on next-generation tumor-infiltrating lymphocyte (TIL) therapies and the groundbreaking potential of KSQ’s CRISPRomics? platform to advance CRISPR/Cas9-engineered eTIL? products. Excited to see these innovations drive the future of cancer treatment! #CellTherapy #TILTherapy #CRISPR